b1 integrins are important regulators of vascular differentiation and development, as their endothelial-specific deletion results in embryonic lethality. In the present study, we investigated the molecular mechanisms underlying the prominent vascular abnormalities that occur in the absence of b1 integrins. Because of the early embryonic lethality of knockout mice, we studied endothelial cell and vessel development in b1-integrin-deficient murine embryonic stem cells to gain novel insights into the role of b1 integrins in vasculo-angiogenesis. We found that vessel development was strongly defective in the mutant embryoid bodies (EBs), as only primitive and short sprouts developed from clusters of vascular precursors in b1 integrin -/-EBs, whereas complex network formation of endothelial tubes was observed in wild-type EBs. The vascular defect was due to deficient b1 integrin expression in endothelial cells, as its endothelial-specific re-expression rescued the phenotype entirely. The mechanism responsible for defective vessel formation was found to be reduced endothelial cell maturation, migration and elongation. Moreover, the lower number of endothelial cells in b1 integrin -/-EBs was due to an increased apoptosis versus proliferation rate. The enhanced apoptosis and proliferation of b1 integrin -/-endothelial cells was related to the elevation of peNOS and pAKT signaling molecules, respectively. Our data demonstrate that endothelial b1 integrins are determinants of vessel formation and that this effect is mediated via different signaling pathways.
INTRODUCTION
Vasculogenesis and angiogenesis are the main processes responsible for embryonic vascular development. The formation of new vascular tubes comprises endothelial cell proliferation and migration as well as the inhibition of apoptosis. Moreover, the surrounding extracellular matrix (ECM) undergoes degradation and remodeling during vascular sprouting. The molecules involved in ECM-cell signaling are the integrin receptors, which are characterized by their bidirectional (outside-in and inside-out) signaling. Integrins bind to ECM proteins such as collagen, laminin and fibronectin and thereby regulate stabilization, migration and the morphology of vascular structures (Senger et al., 2002; Ruoslahti and Engvall, 1997) . Furthermore, integrins interact with intracellular cytoskeletal proteins, providing structure and morphology to the cells (Pozzi and Zent, 2003) . Thus, the role of integrins in matrix adhesion and cytoskeletal reorganization is crucial for cell growth, survival and migration. These key processes are regulated via several integrindependent cross-linked intracellular pathways involving AKT and NO (Abair et al., 2008; Basile et al., 2007; Viji et al., 2009) . Moreover, there is also evidence that integrins are involved in the development of vessels, as deletion of the a5 chain reduced capillary plexus formation (Francis et al., 2002) and avb3 integrins were found to be upregulated in angiogenesis (Brooks et al., 1994) . In particular, b1 integrins have pleiotropic and important functions in vascular development as they were shown to be necessary for teratoma growth and vasculogenesis in embryoid bodies (EBs) (Bloch et al., 1997) . These data are supported by the endothelialspecific deletion of b1 integrins causing early embryonic lethality of mice due to vascular defects (Carlson et al., 2008; Lei et al., 2008; Tanjore et al., 2008) .
To investigate the cellular mechanisms underlying these abnormalities, we chose the embryonic stem (ES) cell system, which is an excellent model to examine the cell biological effects of mutations resulting in early embryonic lethality. We found that b1 integrins regulate key steps of vascular development and network formation, such as endothelial cell maturation, migration and elongation. Proliferation and apoptosis were enhanced by activation of the signaling molecules AKT (AKT1 -Mouse Genome Informatics) and eNOS (NOS3), respectively. Thus, our study provides novel mechanistic insight into the role of b1 integrins for neo-angiogenesis/vascularization.
MATERIALS AND METHODS

Cell culture
The mouse blastocyst-derived ES cell lines D3 (wild-type) and b1 integrin -/-were maintained in culture as described by Fassler (Fassler et al., 1996) . For EB formation cells were cultured in hanging drops for 2 days. Subsequently, the aggregates were incubated for 3 days in suspension and plated on day 5 in a 24-well plate on gelatine-coated coverslips. Experiments were performed after 7, 12, 14 and 18 days, referred to as 5+7, 5+12, 5+14 and 5+18.
Vital microscopy or time-lapse microscopy
In order to live monitor early stages of vasculogenesis, ES cells of the D3 or b1 integrin -/-line were transfected with a PECAM/EGFP construct; after differentiation, clusters of ES cell-derived endothelial precursors were continuously observed for up to 10 hours (Kazemi et al., 2002) with an inverted microscope (Axiovert 100, Zeiss, Goettingen, Germany) equipped with a computer-controlled motorized stage (Merzhaeuser, Nikon, Germany), and a temperature/CO 2 -controlled chamber (Buehler, Nikon). Fluorescence pictures (conventional 100 W halogen lamp) were recorded at 20-minute intervals using a fluorescein isothiocyanate (FITC) filter set as well as an oil-immersion objective 40ϫ (Plan-Neofluar, Zeiss). Images were acquired by a color video camera (Sony, DXC 950P, AVT Horn, Tuebingen, Germany), digitized online via a video frame grabber card (Matrox Corona, Nikon) and controlled by the Lucia software (Nikon). Fluorescence intensity was enhanced employing a video-based buffer device (Sony MPU-F100P, AVT Horn) and the integration mode of the camera.
Magnetic-activated cell sorting
Differentiated ES cells (5+7 days) were dissociated with Accutase. Single cells were stained with the endothelial-specific antibody rat anti-mouse PECAM (1:800, Pharmingen, San Diego, CA, USA) and sorted by magnetic-activated cells (MAC) sorting as previously described (Schmidt et al., 2004) . Briefly, the bead-conjugated secondary antibody, goat anti-rat IgG, was used as described by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). The positive fraction was cultured on gelatine-coated dishes. Cells were used until passage 8. The purity of cells was tested with PECAM staining and amounted to 89% (data not shown). For analysis the number of cells in 40 defined areas was calculated using a 40ϫ objective on an Axiophot (Zeiss, Germany).
Immunohistochemistry, detection of endothelial cells and vessels
For immunofluorescence, single cells or whole EBs (5+7, 5+12, 5+18 days) plated on glass coverslips were fixed with 4% paraformaldehyde (PFA), washed several times with 0.05 M TBS and permeabilized with 0.25% Triton-X 100 and 0.5 M NH 4 Cl in 0.05 M TBS. After blocking with 5% BSA in TBS endothelial cells were stained with the antibody rat anti-mouse PECAM (1:800). Alternatively, double staining was performed with b1 integrin purified mouse anti-CD29 antibody (1:500; BD Bioscience, Erembodegem, Belgium), polyclonal rabbit anti-collagen IV (1:500; Acris Antibodies, Hiddenhausen, Germany), monoclonal mouse anti-fibronectin (1:500; Sigma-Aldrich, Germany), polyclonal rabbit anti-laminin (1:500, Sigma-Aldrich, Munich, Germany) or polyclonal rabbit anti-CD34 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Next, EBs were stained with Cy3-(or Cy2-) conjugated goat anti-rabbit (or goat anti-mouse) IgG (1:1500, and 1:500, Dianova, Hamburg, Germany) or with a biotinylated goat antimouse (or goat anti-rabbit) IgG (1:400, Dako, Glostrup, Denmark) or a biotinylated anti-rat antibody (Amersham Biosciences Europe, Freiburg, Germany) followed by streptavidin-conjugated Cy2 (1:200, Amersham) or Cy3 (1:1500, Amersham). The number of PECAM-positive endothelial sprouts composed of at least five endothelial cells was counted (Schmidt et al., 2004) . For each clone (wild-type or b1 integrin -/-) at least n=9 complete EBs were analyzed. For DAB stainings EBs were incubated overnight at 4°C with the b1 integrin antibody. The secondary antibody was a biotinylated goat anti-mouse antibody (Dako, Glostrup, Denmark), then EBs were labeled with streptavidin-conjugated peroxidase (Amersham) and stained with 3,39-diaminobenzidine as chromogen.
In parallel to the quantification of endothelial sprouts we also classified PECAM-positive structures in four different EBs at early and late stages. We determined 'endothelial precursors' as single endothelial cell precursors, 'clusters' as aggregates of endothelial precursors and 'vessel-like structures' as a network of tube-like structures with at least five branches. The whole EB was screened and results are given as percentage of all PECAM-positive structures.
For single cell counting, EBs were dissociated with trypsin and cells were plated on coverslips. After 24 hours cells were fixed and stained with anti-PECAM antibody and Hoechst dye to label the nuclei. The relative amount of PECAM-positive cells was determined in five fields of sight.
Generation of transgenic ES cell clones
A b1 integrin-mRFP fusion plasmid containing the murine b1 integrin cDNA (2.5 kb EcoRI-AgeI fragment) in frame with mRFP was kindly provided by R. Fässler. By cutting the construct with SalI and AgeI, the b1 integrin cDNA was excised and subsequently cloned into the XhoI and AgeI sites of pEGFP-1 (BD-Biosciences-Clontech, Heidelberg, Germany) containing EGFP under the control of the human PECAM-1 promoter [-4500/+65 PstI fragment in pEGFP-1 (Kazemi et al., 2002) ]. The resulting PECAM-1 promoter/b1 integrin-EGFP fusion construct was used for electroporation of b1 integrin -/-ES cells. Of the construct, 36 mg was linearized by digestion with HindIII restrictase and used for coelectroporation (240 V/500 mF, Bio-Rad Gene Pulser) with 4 mg of the pPWL512 plasmid containing the hygromycin resistance gene under the control of the PGK promoter in 5ϫ10 6 ES cells. Selection was performed by addition of 1000 mg/ml hygromycin.
Tube-forming assay
The spontaneous formation of vessel-like structures by either wild-type or b1 integrin -/-MAC-sorted endothelial cells was performed on a basement membrane matrix preparation (Matrigel, BD Bioscience, Heidelberg, Germany). Plates were coated with Matrigel (10 mg/ml) according to the manufacturer's instructions. Tube formation was monitored during a period of 24 hours using the Axio Observer apparatus (Zeiss, Germany).
Plastic embedding and electron microscopy
EBs were fixed with 4% PFA, rinsed in cacodylate buffer three times and then treated with 1% uranyl acetate in 70% ethanol for 8 hours to enhance the contrast. The specimens were subsequently dehydrated in a graded series of ethanol and then embedded in Araldite (Serva, Heidelberg, Germany). Semithin sections (500 mm) were cut with a glass knife on an ultramicrotome (Reichert, Bensheim, Germany) and stained with Methylene Blue. Ultrathin sections (30 to 60 nm) for electron microscopy were processed on the same microtome with a diamond knife and placed on copper grids. Transmission electron microscopy was performed using a 902A electron microscope from Zeiss.
Morphological analysis and confocal microscopy
The distribution pattern of extracellular matrix proteins was analyzed by confocal microscopy using the LSM 510 META Zeiss microscope (Zeiss Microimaging, Goettingen, Germany). Images were acquired in the multitrack mode, collected at 512ϫ512 pixels. Cy3 was excited at 488 nm (AI laser), Cy2 at 543 nm (HeNe laser). After the main dichroic beam splitter (HFT 488/543 for Cy3 and Cy2), the fluorescence signal was divided by a secondary dichroic beam splitter (NFT 543) and detected in the separate channels using the appropriate filters: BP 505-530 (for Cy2), LP560 (for Cy3). In this set-up, no crosstalk between the green and red channels was observed. Pictures of whole EBs were acquired with an Axiovert 200 (Zeiss) and assembled by the mosaix function. Automated area analysis of whole EBs was performed by the AutMess program of the AxioVision 4.6 software (Zeiss).
Western blot
For western blotting, samples were lysed in SDS sample buffer and submitted to SDS-PAGE on a 4-15% gradient TRIS-HCl gel (Criterion, BioRad Laboratories, Germany). Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and incubated with the antibodies described above. Immunoreactive proteins were detected by the enhanced chemiluminescence detection system (Amersham Biosciences Europe). Phosphorylated proteins were detected by rabbit anti-pAKT (Ser473) (1:1000, Cell Signaling, Danvers, MA, USA) and rabbit anti-peNOS (Ser1177) (1:500, Upstate, Hamburg, Germany). These were compared to AKT (1:500, Biomol, ENZO LIFE SCIENCES, Lörrach, Germany) and eNOS (1:500, Millipore, Billerica, MA, USA) expression. For the detection of b1 integrins a polyclonal antibody (1:500, Abcam, Cambridge, UK) was applied. As secondary antibody a polyclonal anti-rabbit antibody was used (1:500, Biomol, Hamburg, Germany).
Proliferation assay
EBs from wild-type and b1 integrin -/-clones were fixed with 4% PFA and used for immunohistochemistry. After identifying the endothelial cells by PECAM staining, proliferating cells were detected with the primary antibody rabbit anti-mouse-Ki67 (1:150, pAb, Dianova, Hamburg, Germany); as secondary antibody goat anti-rabbit CY2 (1:200, Dianova, Hamburg, Germany) was used. To determine the number of proliferating endothelial cells Ki67-positive cells in 50 randomly chosen vessel-like tubes were analyzed (Muller-Ehmsen et al., 2006).
Apoptosis assay
Wild-type and b1 integrin -/-EBs were fixed and stained with PECAM antibody as described above. Apoptotic cells were detected with a rabbit anti-PARP p85 fragment antibody (1:250 Promega, Madison, WI, USA); as secondary antibody goat anti-rabbit Cy2 was used. To evaluate the number of apoptotic endothelial cells the number of PARP-cleavage-positive cells within 50 randomly chosen vessel-like tubes was counted.
Migration assay
Migration-assay was performed in a modified Boyden chamber by using a 24-well HTS Fluoro Blok insert system (Falcon Becton Dickinson, Heidelberg, Germany). The inserts of the chamber consist of a polyethylene membrane with 8.0 mm pores blocking >99% of the transmission light (490-700 nm). Inserts were coated with 0.1% gelatine solution for 1 hour. EBs (5+7), dissociated with Accutase (PAA Laboratories, Linz, Austria), were MAC sorted with a PECAM antibody. Thereafter, cells were put on top of an insert and incubated for 8 hours in DMEM with 15% FCS. Cells were counted after 8 hours of migration to exclude proliferation as potential mechanism (Schmidt et al., 2004) . For analysis, the membrane was cut out of the insert, cells were stained with anti-PECAM antibody and covered in DAPI mounting medium (4Ј,6-diamidino-2-phenylindole; Vectashield, Vector Laboratories, Burlingame, CA, USA). The number of migrating PECAM-positive cells was counted. Because the rescue clone did not tolerate MAC sorting, whole EBs were dissociated and the number of PECAM-positive cells was determined before and after migration. Before migration, the amount of PECAM-positive cells was equal in wild type (8100±220, n=3), b1 integrin -/-(7520±440, n=3) and the rescue clone (7364±640, n=3, P>0.05); therefore we directly compared absolute values after migration.
Inhibitor treatment
In the case of EB treatment with inhibitors, the PI3K blocker wortmannin (25 nM) was applied for 30 minutes, and the eNOS inhibitor L-NAME (100 mM) for 12 hours.
Statistical analysis
All data are presented as mean±s.e.m. Data analysis was performed using analysis of variance with Bonferroni post-hoc test and/or Student's t-test for unpaired data. P<0.05 was considered to be significant. 
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RESULTS
Lack of b1 integrin impairs vessel formation and inhibits maturation of endothelial cells during development
To gain mechanistic insight into the role of b1 integrins in embryonic vessel development, the endothelial cells and the formation of tubelike structures in wild-type and b1 integrin -/-EBs were analyzed and quantified at different time points. Wild-type EBs showed clusters of endothelial precursors (arrow) as well as complex networks of endothelial tubes at early (5+7) and late (5+14) developmental stages (arrowhead) (Fig. 1A-C) . By contrast, in the b1 integrin -/-EBs only primitive and short sprouts were detected at both stages ( Fig. 1D-F) . Although the total amount of endothelial cells per EB was not different at day 5+7 (see below), the number of endothelial tubes in the b1 integrin -/-EBs was strongly reduced compared with wild-type EBs at all differentiation stages (Fig. 1G ). To analyze in detail the differences in vascular development, we distinguished three developmental stages of endothelial structures in EBs: (1) single endothelial precursor cells; (2) clusters of endothelial precursors; and (3) vessel-like structures (see also Materials and methods). In early stage (5+7) wild-type EBs (n=4), 13% of PECAM-positive cells were single endothelial precursors, 36% were arranged in clusters and 51% were in vessellike structures, whereas in b1 integrin -/-EBs (n=4) 81% were single endothelial precursors, 15% were found in clusters and 4% were in vessel-like structures. In late stage (5+14) wild-type EBs (n=4), a low percentage of endothelial precursors (4%) and similar amounts of clusters (47%) and vessel-like structures (49%) were detected, whereas in b1 integrin -/-EBs (n=4), high numbers (87%) of endothelial precursors persisted and again only low numbers of more differentiated forms (clusters 13%, no vessel-like structures) could be found. These results clearly demonstrate that the formation of vessellike structures from endothelial precursors is impaired at all stages in the absence of b1 integrins.
The increased percentage of endothelial precursors in b1 integrin -/-EBs suggested a defect in endothelial cell differentiation. Therefore we investigated in more detail the maturation stage of the MAC-sorted endothelial cells by co-staining with PECAM and CD34, a marker for cells of an early maturation stage. We found a strong increase of the PECAM-positive/CD34-positive cells in the b1 integrin -/-compared with wild-type endothelial cells (ratio PECAM and CD34-positive/PECAM-positive cells: 50.0±2.2%, n=7, b1 integrin -/-versus 24.3±2.0% n=8, wild-type, P<0.001). Moreover, the area of EBs covered by endothelial cells was equal at the early stage (5+7) but declined at the late stage (5+14) in b1 integrin -/-EBs ( Fig. 1I-K) . These results were corroborated by endothelial cell counting after single-cell dissociation (Fig. 1L) . Thus, in b1 integrin -/-EBs there is a high proportion of early-stage endothelial cells, and this clearly shows that b1 integrin expression is a prerequisite for endothelial cell maturation and vascular tube formation. As these defects persisted in late-stage EBs and the number of endothelial cells declined, the observed phenotype is not due to a mere delay in cell maturation.
b1-integrin-deficient EBs display morphological defects in endothelial tube formation
To directly monitor and determine the dynamics of endothelial cell development in b1 integrin -/-EBs, we established stable transgenic wild-type and b1 integrin -/-ES cell lines, in which the endothelialspecific promoter PECAM drives the expression of EGFP (Kazemi et al., 2002) . Time-lapse microscopy revealed that sprouting endothelial tubes developed from endothelial cell clusters within 8 hours in wild-type EBs by elongation and migration of endothelial cells ( Fig. 2A-C, arrow) . By contrast, the endothelial cells in the b1 integrin -/-EBs remained round and displayed less migration, resulting in a lack of tube formation and branching during the same period of observation (Fig. 2D-F) (n=4) . These findings are in full agreement with earlier reports in vivo, and our results in EBs where the amount of vascular tubes was strongly reduced (see above), and indicate that the deletion of b1 integrin inhibits the development of endothelial tubes in the early phases of vascular development (Carlson et al., 2008; Lei et al., 2008; Tanjore et al., 2008) .
b1 integrins regulate ECM formation
Integrins are important receptors for the interaction of endothelial cells with the ECM, which is a prerequisite for adhesion, migration and differentiation of early endothelial cells. Our ultrastructural analysis revealed an intact basal membrane (BM) around endothelial cells in wild-type EBs, whereas only fragments of BM in b1 integrin -/-EBs were found (arrows, Fig. 3A) . Next, we examined in detail the deposition of BM proteins in wild-type and b1 integrin -/-
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Development 137 (6) EBs at 5+7 days. Collagen IV, laminin and fibronectin (all green) were found to be highly expressed around PECAM-positive tubelike structures (red) in wild-type EBs (Fig. 3B ,C,D left panel). However, in b1 integrin -/-EBs, collagen IV and laminin were completely absent (Fig. 3B ,C middle panel), whereas fibronectin deposition was found throughout the whole EB but not around the vascular structures (Fig. 3D) . Thus, b1 integrins in endothelial cells are a prerequisite for ECM deposition around vascular structures.
Impaired vascular tube formation is due to the lack of b1 integrins in endothelial cells
We next determined whether the defect of vasculo-angiogenesis in b1 integrin -/-EBs was due to b1 integrin deficiency in endothelial cells or secondary to a lack of b1 integrins in surrounding cells. For this purpose we used MAC-sorted endothelial cells and transferred them to Matrigel. Whereas wild-type endothelial cells formed aggregates and tube-like structures (Fig. 4A-C) , b1 integrin -/-endothelial cells did not assemble or develop any tube-like structures (Fig. 4D-F) . These data suggest that the lack of expression of b1-integrins in endothelial cells underlies the massive cell biological defects in tube formation and that this defect cannot be compensated by an intact ECM.
To further corroborate this crucial point, we designed a rescue approach and generated stable transgenic ES cell lines in which b1 integrin was re-expressed as fusion protein with EGFP under control of the endothelial-specific PECAM promoter. In these rescue EBs we found EGFP-positive clusters of endothelial cells (Fig. 5A) , which further developed into sprouting endothelial tubes (Fig. 5B) , recapitulating the qualitative and quantitative features of vessel formation in wild-type EBs. In fact, large and elongated tube-like structures were found in these rescued EBs; note that EGFP fluorescence was decreased in more differentiated vessel structures, most likely because of the lower rate of protein synthesis (Fig. 5C ). We also assessed b1 integrin expression with DAB immunostaining and found specific re-expression in vessellike structures of rescue EBs (Fig. 5G,H) , whereas no signal was found in b1 integrin -/-EBs (data not shown). In addition, we investigated the subcellular distribution of b1 integrins in endothelial cells with double immunofluorescence and detected their preferential membrane localization in wild-type and rescue cells (Fig. 5D-F) . Western blot experiments revealed that b1 integrin protein expression was completely absent in b1 integrin -/-EBs and partly restored in the rescue clone (Fig. 5I) . The number of vessel-like structures in the rescue clones at day 5+7 was similar to that found in wild-type EBs (Fig. 5J) ; also the distribution of endothelial precursors, clusters and vessel-like structures was very similar to wild-type EBs: 15, 27 and 58% (n=4), respectively (Fig.  5K) .
In the rescue clones collagen IV, laminin and fibronectin deposition around vascular structures was restored, indicating that the b1 integrin expression in endothelial cells is sufficient for the BM assembly around PECAM-positive tube-like structures (Fig.  5L,M,N) . Conversely, the Matrigel experiments demonstrate that an intact matrix surrounding endothelial cells is not sufficient for vascular network formation in the absence of b1 integrins in endothelial cells.
Thus, the reduced number of vessel-like structures, the defective sprouting and the lack of ECM protein deposition around endothelial cells in b1 integrin -/-EBs is clearly due to the absence of endothelial b1 integrins and independent from the b1 integrin expression in surrounding cells.
Lack of endothelial b1 integrins enhances proliferation and apoptosis but reduces migration in endothelial cells
Vascular development strongly relies on proliferation, apoptosis and migration of endothelial cells (Kalluri, 2003; Davis and Senger, 2005) . Co-staining with antibodies against the proliferation marker Ki67 and the endothelial cell marker PECAM revealed a significant increase in the proliferation rate of endothelial cells in b1 integrin -/-EBs ( Fig. 6A ; see also Fig. 6D  for immunohistochemistry) . As the high proliferation rate does not match with the lower numbers of endothelial cells in latestage EBs in b1 integrin -/-EBs, we also determined the rate of apoptosis. Double staining with antibodies against the apoptosis marker Poly(ADP-Ribose)-polymerase cleavage fragment (PARP, -/-EBs (right) no collagen IV or laminin was found, whereas fibronectin was deposited throughout the EB in a punctate manner. Scale bars: 100 nm in A; 40 mm in B.
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p85 fragment) and PECAM also showed a strong increase of apoptotic nuclei in endothelial cells per 50 vascular tubes in the b1 integrin -/-EBs ( Fig. 6B ; see also Fig. 6E for immunohistochemistry). At late stage the ratio of apoptotic/ proliferating cells was 2.38 times higher in b1 integrin -/-endothelial cells compared with wild type, clearly explaining their reduction in b1 integrin -/-EBs over time. The high levels of proliferation and apoptosis in b1 integrin -/-EBs were reverted to wild-type levels in the rescue clones (Fig. 6F,G) .
As migration of endothelial cells is crucial for sprouting in vasculogenesis and angiogenesis (Schmidt et al., 2004) , we determined this parameter in a modified Boyden chamber. We found decreased migration of PECAM-positive MAC-sorted b1 integrin -/-endothelial cells (Fig. 6C) . The rescue clones showed a recovered migratory function (Fig. 6H) . Similar results were obtained at 5+14 days. Thus, the lack of b1 integrins in endothelial cells decreases cell survival and migration of the developing vasculature.
Activation of PI3K/AKT is responsible for increased proliferation, whereas the induction of eNOS/NO promotes apoptosis in b1 integrin -/-endothelial cells The PI3K/AKT/eNOS signaling pathway is central for endothelial cell biology. PI3K/AKT has been reported to increase endothelial cell proliferation and migration and to inhibit apoptosis (Ackah et al., 2005; Deregibus et al., 2003; Radisavljevic et al., 2000) . In addition, NO is known to induce in a dose-dependent manner proliferation and apoptosis in endothelial cells (Papapetropoulos et al., 1997; Shen et al., 1998) . We have examined the expression of these key signaling molecules using western blot analysis and found an increase in the activated pAKTSer473 and peNOSSer1177 in b1 integrin -/-EBs (Fig. 7A ) when compared with wild-type EBs; in the rescue clone, that increase was reverted. Thus, the deletion of b1 integrins in endothelial cells increases the amount of pAKTSer473 and peNOSSer1177. Interestingly, the expression of pERK1/2, a molecule that is known to promote FGF-dependent migration (Pintucci et al., 2002) , was found to be reduced in b1 integrin -/-EBs, whereas its expression returned to normal in the rescue clone (data not shown).
To investigate the relevance of the of PI3K/AKT and eNOS/NO pathways in wild-type and b1 integrin -/-endothelial cells, we determined proliferation, apoptosis and migration in the presence of the PI3K blocker wortmannin (WN, 25 nM) or the eNOS inhibitor L-NAME (100 mM). We also tried LY294002, another blocker of the PI3K, but this substance had toxic effects and could therefore not be used.
Our data reveal that the proliferation rate was independent from PI3K/AKT in wild-type EBs, as blockade with wortmannin showed no effect. However, in b1 integrin -/-EBs wortmannin led to a significant decrease of proliferation rates in endothelial cells (Fig.  7B) . Moreover, proliferation turned out to be independent from eNOS/NO, as L-NAME had no effect in both wild-type cells and b1 integrin -/-cells (Fig. 7C ). The rate of apoptosis was not affected by the activation of the PI3K/AKT pathway in wild-type and b1 integrin -/-endothelial cells (Fig. 7D) . In wild-type endothelial cells there was also no influence of eNOS/NO on. By contrast, inhibition of eNOS/NO decreased apoptosis in b1 integrin -/-endothelial cells (Fig. 7E) . Finally, there was no evidence for a contribution of the PI3K/AKT or eNOS/NO pathway to decreased migration rates in b1 integrin KO endothelial cells.
These results illustrate that high proliferation levels are induced by PI3K/AKT activation and that high apoptosis rates are a result of eNOS/NO increase in b1 integrin -/-endothelial cells.
DISCUSSION
In the present study we demonstrate a central role for b1 integrins in embryonic vasculogenesis and angiogenesis. We have found intact endothelial cells in b1 integrin -/-EBs at different time points during development; however, their sprouting and vascular network formation was strongly reduced. Even though the number of PECAM-positive cells is unaltered at the early stage in b1 integrin -/-EBs, the increased amount of CD34/PECAM-positive endothelial cells and the reduction of vessel-like structures suggest that the endothelial cells arrest at earlier developmental stages and cannot form/maintain vessel tubes, which indicates impaired endothelial cell differentiation and defective blood vessel formation. These novel findings are in full agreement with the strongly defective vascularization reported for b1 integrin -/-
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Development 137 (6) embryos (Carlson et al., 2008; Lei et al., 2008; Tanjore et al., 2008) . In contrast to these earlier in vivo studies, our approach using ES cells allowed us to investigate the underlying mechanism by studying endothelial cell differentiation and vessel formation at different time points using a variety of cell biological assays.
We have identified several crucial defects of vascular development -reduced migration and elongation and enhanced apoptosis/proliferation ratio of endothelial cells, as well as defective ECM protein deposition -in b1 integrin -/-endothelial cells that mechanistically explain the defective vascularization. An important finding was that these defects were entirely dependent on the lack of endothelial b1 integrins, as our rescue approach restored the wild-type phenotype. Migration, elongation and proliferation of endothelial cells are crucial for vascular sprouting and branching, and this process is known to rely on the contact of the cells with ECM molecules via integrins (Davis and Senger, 2005; Qutub and Popel, 2009; Senger et al., 2002) . Accordingly, Boyden chamber assay and time-lapse microscopy revealed a strong reduction of migration and a lack of elongation of endothelial cells. This result in combination with the enhanced apoptosis/proliferation ratio is most likely responsible for defective sprouting and tube formation in b1 integrin -/-EBs. Enhanced proliferation rates are also supported by an earlier study in which b1 integrin deletion increased proliferation in smooth muscle cells (Abraham et al., 2008) . Similarly, apoptosis rates are expected to increase in endothelial cells because of the lack of adhesion to the matrix (Frisch and Francis, 1994) . In contrast to our data, Carlson et al. found no alterations in the proliferation rate of endothelial cells after b1 integrin deletion (Carlson et al., 2008) . These differences could be explained by compensatory effects occurring in the in vivo situation. At the early stage we found no difference in the amount of endothelial cells in b1 integrin -/-and wild-type endothelial cells. As in late-stage b1 integrin -/-PECAM-positive cells the balance of proliferation versus apoptosis shifts to the latter, the overall number of endothelial cells declined, which explains their strong reduction at day 5+14. Besides the reduced total amount of PECAM-positive cells, vascular network formation was strongly impaired at all differentiation stages in the b1 integrin -/-EBs, and this is most likely due to the strongly altered migration rates, which prevent sprouting and tube formation. As high relative numbers of endothelial precursors and low relative numbers of vessel-like structures persist at all differentiation stages in the b1 integrin -/-EBs, this is not due to a delay in vascular development but indicative of a general maturation defect. This finding is further supported by the increased amount of CD34-positive endothelial cells in b1 integrin -/-EBs; these data indicate that endothelial cell assembly and maturation are strongly disturbed. Our data also provide a novel mechanistic explanation for altered survival of endothelial cells in b1 integrin -/-EBs. We have identified increased PI3K/AKT activation as underlying the enhanced proliferation of endothelial cells and augmenting eNOS/NO activity to cause the elevated apoptosis. The PI3K/AKT cascade has been shown in earlier studies to be an important regulator of proliferation (Madeddu et al., 2008; Steinle et al., 2002) , whereas apoptosis is well known to be promoted by high levels of NO (Lopez-Farre et al., 1998) . The fact that inhibitors of both molecules had no impact on proliferation and apoptosis rates of wild-type endothelial cells demonstrates that these molecules determine endothelial growth and survival in our system only at the high expression levels found in the knockout. Whether defective sprouting and vascular development is purely a result of the above reported alterations of signaling pathways and/or also because of the lack of adhesion to ECM molecules remains to be investigated in future. Previous studies reported that the absence of b1 integrins leads to defects in BM assembly (Aumailley et al., 2000; Li and Yurchenco, 2006; Lohikangas et al., 2001) . In particular, the lack of fibronectin, a major ligand at b1a5 integrins, has been implicated in severe vascular defects (Yang et al., 1993) . In accordance with those findings we demonstrate that lack of endothelial b1 integrins results in the complete absence of such important matrix proteins as collagen IV, laminin and fibronectin around endothelial cells. This clearly suggests that the deposition of these proteins is b1 integrin dependent. In addition, our Matrigel experiments also show that even intact ECM is not sufficient for the formation of vascular networks from b1 integrin -/-endothelial cells but that adhesion to the ECM via b1 integrins is crucial for endothelial tube formation.
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Development 137 (6) Taken together, our current study provides a novel mechanistic explanation for defective vascularization after b1 integrin deletion. We found that the lack of endothelial b1 integrins inhibited endothelial cell maturation, migration and sprouting, which resulted in defective vascular network formation. Moreover, the lack of b1 integrins induced endothelial cell proliferation and apoptosis via PI3K/AKT and eNOS/NO activation, respectively. This led to an enhanced apoptosis/ proliferation ratio, explaining the decreased number of endothelial cells during the differentiation. These new insights into the mechanism of how b1 integrins promote vascularization could be also exploited for therapeutic purposes to re-vascularize ischemic tissues or to inhibit tumor angiogenesis. RESEARCH ARTICLE b1 integrins in vascular development Fig. 7 . Protein expression of pAKT, peNOS and proliferation, apoptosis and migration after blockade of the PI3K/pAKT and peNOS/NO pathways. (A) PeNOSSer1177 and pAKTSer473 expression were increased in b1 integrin -/-compared with wild-type EBs. After re-expression of b1 integrin in the rescue clone these alterations were reverted to wild-type levels. (B,C) Proliferation was decreased by wortmannin in b1 integrin -/-endothelial cells (B), whereas L-NAME was without effect (C). (D,E) Apoptosis was decreased by L-NAME in b1 integrin -/-endothelial cells, whereas wortmannin was without effect, *P<0.05, ANOVA.
